Fluorescent biomarkers targeting cancer detection
Summit Biomedical Imaging develops PARP-targeted fluorescent biomarkers to help clinicians detect and remove cancers more effectively.
Built on the science of fluorescent detection
Summit Biomedical Imaging was founded to solve a critical problem in cancer surgery: clinicians couldn't reliably see all tumor tissue during removal. We developed fluorescent biomarkers targeting PARP, an enzyme overexpressed by many cancers, enabling real-time visualization that improves surgical outcomes and patient survival rates.
Advancing cancer detection and surgical precision
Summit Biomedical Imaging's fluorescent biomarkers are improving how clinicians find and remove cancer, delivering measurable benefits to patients and the medical community.
100%
PARP enzyme targeting
Our biomarkers specifically identify cancers that overexpress PARP, enabling precise detection.
2+
Cancer types addressed
Fluorescent diagnostics support clinicians across multiple cancer types with enhanced visibility.
1
Dedicated team member
Summit's focused expertise drives innovation in fluorescence-based surgical support solutions.
1
Global mission
Summit aims to become the world leader in fluorescence-based diagnostics and surgical support.
Common questions about Summit Biomedical Imaging
Learn more about our fluorescent biomarker technology, mission, and impact on cancer detection and surgical support.
What are fluorescent biomarkers and how do they work?
Fluorescent biomarkers are molecules that bind to specific enzymes, like PARP, that are overexpressed in cancer cells. When exposed to specific light wavelengths, they fluoresce, allowing clinicians to visualize cancer tissue during surgery for more complete removal and better patient outcomes.
Why does PARP targeting matter for cancer detection?
PARP is an enzyme many cancers depend on for survival and repair. By targeting PARP with our fluorescent biomarkers, clinicians gain real-time visibility of tumor tissue, enabling more precise surgical decisions and reducing the risk of leaving cancer behind.
How does Summit Biomedical Imaging's technology improve surgical outcomes?
Our fluorescent biomarkers light up cancer cells during surgery, giving surgeons clear visual guidance to identify and remove affected tissue more completely. This precision can reduce recurrence risk and improve long-term patient survival rates.
What is Summit Biomedical Imaging's mission?
We aim to become the world leader in fluorescence-based diagnostics and surgical support. Our goal is to advance cancer detection and treatment through innovative biomarker technology that improves patient outcomes and transforms how clinicians approach cancer care.
Who benefits from fluorescence-based surgical technology?
Patients with PARP-overexpressing cancers benefit most, as do the surgeons and oncologists treating them. Our technology enables clinicians to make more informed decisions during surgery, potentially reducing complications and improving survival rates across multiple cancer types.
Is Summit Biomedical Imaging's technology available now?
Summit is actively developing and refining our fluorescent biomarker platform. We work with clinical and research partners to advance the technology toward regulatory approval and clinical use. Contact us to learn about ongoing studies and partnerships.
Have more questions?
Reach out to our team to discuss our technology, partnerships, or clinical applications in detail.